First-line immune checkpoint inhibition is more cost-effective than chemotherapy for treatment-naïve, BRAF wild-type, stage IV melanoma.
Olaparib significantly prolonged progression-free survival compared with chemotherapy among patients with HER2-negative breast cancer.
Nivolumab was clinically active and well-tolerated among patients with treatment-refractory metastatic squamous cell carcinoma of the anal canal (SCCA).
Reducing the cyclophosphamide dose for a subset of patients with rhabdomyosarcoma may increase the risk of disease recurrence.
Active surveillance appears to be a safe alternative to primary intervention for selected patients with small renal masses.
Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy.
Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.
Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.
Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors.
Pembrolizumab following platinum-based chemotherapy was associated with significantly longer overall survival, fewer adverse events.
David J. McConkey, MD, PhD, described how genomics can affect the clinical management of patients with bladder cancer.
The clinical outcomes when using neoadjuvant chemotherapy for muscle-invasive bladder cancer vary by molecular subtype.
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
Full-length androgen receptor (AR-FL) copy number derived from circulating tumor cells detected using a liquid biopsy.
A phase 3 study presented at the 2017 Genitourinary Cancers Symposium demonstrated the feasibility of conducting adjuvant trials.
Researchers identified nearly 80 significantly mutated genes in prostate cancer, including many novel genes and pathways.
The Decipher genomic classifier obtained from biopsy samples was prognostic for distant metastases and prostate cancer-specific mortality.
Despite early failures, there may be a role for single-agent and combination immunotherapy for patients with prostate cancer.
The risk for developing prostate cancer is more than 5 times higher for men in the top 1% of the genetic risk score group.
By potentially affecting the disease biology of chronic myeloid leukemia (CML), smoking may increase the risk of death.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|